altRx vs Hers: Compounded pricing vs FDA-approved Wegovy® options

Quick verdict: altRx vs Hers — lower-cost compounded meds versus FDA-approved brand options

The comparison altRx vs Hers comes down to a clear trade-off: altRx emphasizes affordability with compounded semaglutide from $89/mo and compounded tirzepatide from $149/mo plus 100% online visits and free 2-day delivery, while Hers emphasizes FDA-approved brand-name options such as Wegovy® from $149/mo and a personalized care team with dose check-ins. This means choose altRx for lower starting prices and choose Hers for FDA-approved brand medication.

Start altRx pricing quiz

How pricing and medication type differ

altRx advertises semaglutide from $89/mo and tirzepatide from $149/mo, describing those products as compounded. Hers lists Wegovy® (brand-name semaglutide) from $149/mo and notes that it offers FDA-approved brand-name GLP-1 options. altRx states its limited offer directly as compounded semaglutide $89/mo and compounded tirzepatide $149/mo; Hers states Wegovy® is FDA-approved and not compounded, with medication prices starting from $149/mo and higher tiers for other brand options.

Membership, billing, and what the price includes

altRx says there are no membership, insurance or hidden fees and highlights all-inclusive monthly pricing that covers medical oversight, medication, and 24/7 support; altRx also lists buy now pay later options. Hers requires an active Weight Loss Membership for medication access and notes membership fees billed separately (for example a $39 first month and auto-renews at $149/mo thereafter as captured). Hers indicates medication pricing may be billed separately and that medication is not available without an active membership.

Care model and delivery

altRx emphasizes 100% online medical visits, a 2-minute quiz to get started, and free, discreet 2-day delivery when prescribed. Hers highlights a personalized care team with ongoing dose check-ins and offers FDA-approved brand options; Hers also notes that some medications like Ozempic® may be prescribed off-label at a clinician’s discretion and that prescriptions are subject to clinical eligibility.

Regulatory and availability notes

Both sources include regulatory clarifications: altRx explicitly notes that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Hers emphasizes that brand-name options it offers, such as Wegovy® and Zepbound®, are FDA-approved for weight loss, while also noting not all products are available in all states and that clinical eligibility is required for some medications.

Side-by-side at-a-glance comparison

These differences shape who each provider is best for: altRx is positioned around affordability and a fully online process using compounded products; Hers is positioned around FDA-approved, brand-name options with an integrated team and membership model.

Compare altRx plans now

What we did not find in the source

The supplied evidence does not include direct clinical outcome comparisons, comprehensive state-by-state availability lists for Hers, or FDA approval status for every branded product beyond those named. Pricing examples and promotional phrasing were taken exactly as provided.

Start altRx enrollment

Conclusion: How to choose between altRx vs Hers

Choose altRx if you prioritize lower starting prices, a 100% online experience, no membership fees, and are comfortable with compounded semaglutide or tirzepatide that are not FDA-approved. Choose Hers if you prioritize access to FDA-approved brand-name options such as Wegovy®, want a personalized care team with dose check-ins, and are prepared for a required membership and separate medication billing.